Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease

NCT02738905 is registered in ClinicalTrials.gov with Jason Stubbs, MD as lead sponsor.

NCT NCT02738905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02738905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease
Lead sponsor
Jason Stubbs, MD
Phase
Phase 1
Overall status
Withdrawn
Start date
January 31, 2016
Completion date
February 26, 2019
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease